Provided by Tiger Fintech (Singapore) Pte. Ltd.

Petra Acquisition Inc

8.32
0.0000
Volume:- -
Turnover:468.55K
Market Cap:54.53M
PE:-29.89
High:8.32
Open:8.32
Low:8.32
Close:8.32
Loading ...

Petra Acquisition, Inc. Announces Share Redemption Backstop and Forward Purchase Agreements in Connection with Revelation Biosciences, Inc. Business Combination

GlobeNewswire
·
22 Dec 2021

Petra Acquisition, Inc. Announces Special Meeting of Stockholders to Approve Business Combination with Revelation Biosciences, Inc.

GlobeNewswire
·
17 Dec 2021

Revelation Biosciences Inc. Appoints Joseph A. Bellanti, M.D. to Scientific Advisory Board

GlobeNewswire
·
07 Dec 2021

Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza

GlobeNewswire
·
02 Dec 2021

Revelation Biosciences Inc. Announces Creation and Appointments to Scientific Advisory Board

GlobeNewswire
·
29 Nov 2021

BRIEF-Revelation Biosciences Initiates Phase 1B Study Of Allergic Rhinitis And Chronic Nasal Congestion Treatment

Reuters
·
15 Nov 2021

Revelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhinitis and Chronic Nasal Congestion

GlobeNewswire
·
15 Nov 2021

Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)

GlobeNewswire
·
26 Oct 2021

Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion

GlobeNewswire
·
04 Oct 2021

Revelation Biosciences Receives Approval To Initiate Phase 2B Viral Challenge Study Of REVTx 99 For Prevention Of Respiratory Viral Infections

T-Reuters
·
28 Sep 2021

Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections

GlobeNewswire
·
28 Sep 2021

Respiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal For NASDAQ Debut

Benzinga
·
31 Aug 2021

BRIEF-Revelation Biosciences, Inc., A Life Sciences Company Developing Therapeutics And Diagnostics For Respiratory Viral Infections, Including Covid-19, To Become Publicly Traded Through A Merger With Petra Acquisition, Inc.

Reuters
·
30 Aug 2021